{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LVAYRGOA/a2dd5db6-b9f3-4e26-b390-b609e97fc83b/PDF","dcterms:extent":"184 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-LVAYRGOA/4fff3cec-2832-4b6f-8f86-0732879fcad5/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-LVAYRGOA","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2016","dc:creator":"Lunder, Mojca","dc:format":[{"@xml:lang":"sl","#text":"številka:2/3"},{"@xml:lang":"sl","#text":"letnik:67"},{"@xml:lang":"sl","#text":"str. 193-199"}],"dc:identifier":["ISSN:0014-8229","COBISSID:4081777","URN:URN:NBN:SI:doc-LVAYRGOA"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"brezglutenska dieta"},{"@xml:lang":"sl","#text":"Celiakija"},{"@xml:lang":"sl","#text":"gluten"},{"@xml:lang":"sl","#text":"laktazna persistenca"},{"@xml:lang":"sl","#text":"laktozna intoleranca"},{"@xml:lang":"sl","#text":"Patogeneza"},{"@rdf:resource":"http://www.wikidata.org/entity/Q188251"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Celiakija in laktozna intoleranca| Celiac disease and lactose intolerance|"},"dc:description":[{"@xml:lang":"sl","#text":"Celiac disease and lactose intolerance are closely related to wheat and milk, the two fundamental foods that entered human diet since the beginning of agriculture and animal husbandry ten thousand years ago. Celiac disease is chronic systemic autoimmune disorder that occurs among genetically predisposed subjects who are exposed to glutencontaining foods and other environmental factors. Correct diagnosis is essential for efficient and rational treatment and depends on non-avoidance of gluten containing foods beforehand. Despite novel treatment investigations and progress in understanding mechanisms of celiac disease, there is no pharmacotherapy in clinical practice yet. Lactose intolerance is a consequence of lactose malabsorption, due to reduced action of lactase. Primary lactose intolerance is a normal condition, present in 65 percent of adult population. To relieve gastrointestinal symptoms reduction of lactose intake is recommended. Complete restriction is unnecessary, since most lactose intolerant individuals can ingest small amounts of lactose. Lactose free milk products and supplements containing lactase are also available"},{"@xml:lang":"sl","#text":"Celiakija in laktozna intoleranca sta povezani z žiti in mlekom, razširjenimi živili, ki jih iz evolucijskega vidika uživamo šele kratek čas, od pojava kmetijstva in živinoreje. Celiakija je kronična sistemska avtoimunska bolezen, ki nastane pri osebah z genetsko predispozicijo, v kombinaciji z nekaterimi okolijskimi dejavniki in vnosom glutena s hrano. Uspešno in smiselno zdravljenje celiakije je odvisno od pravilne diagnoze, pred katero vnosa glutena ne smemo omejiti. Glavni način zdravljenje celiakije je brezglutenska dieta. Navkljub iskanju novih načinov zdravljenja in velikemu napredku pri poznavanju mehanizmov celiakije farmakoterapije v klinični praksi še ni. Laktozna intoleranca je posledica nezadostne razgradnje laktoze v prebavnem traktu, zaradi zmanjšanega delovanja laktaze. Primarna laktozna intoleranca je normalno stanje, do katerega pride pri 65-odstotkih odraslih. Pri odpravljanju prebavnih težav priporočajo zmanjšanje vnosa laktoze. Popolno izogibanje ni potrebno, saj lahko večina ljudi z laktozno intoleranco prebavi manjše količine laktoze. Na voljo so tudi mlečni izdelki brez laktoze in prehranska dopolnila z laktazo"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-LVAYRGOA","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-LVAYRGOA"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-LVAYRGOA/a2dd5db6-b9f3-4e26-b390-b609e97fc83b/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-LVAYRGOA/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-LVAYRGOA"}}}}